🚀 VC round data is live in beta, check it out!
Neurizon Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Neurizon Therapeutics and similar public comparables like Rallybio, Dare Bioscience, Atara Biotherapeutics, Intervacc and more.
Neurizon Therapeutics Overview
About Neurizon Therapeutics
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).
Founded
2000
HQ
Employees
14
Website
Sectors
Financials (FY)
EV
$39M
Neurizon Therapeutics Financials
Neurizon Therapeutics reported last fiscal year revenue of $2M and negative EBITDA of ($4M).
In the same fiscal year, Neurizon Therapeutics generated $1M in gross profit, ($4M) in EBITDA losses, and had net loss of ($4M).
Neurizon Therapeutics P&L
In the most recent fiscal year, Neurizon Therapeutics reported revenue of $2M and EBITDA of ($4M).
Neurizon Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 72% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (206%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (131%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (220%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Neurizon Therapeutics Stock Performance
Neurizon Therapeutics has current market cap of $43M, and enterprise value of $39M.
Market Cap Evolution
Neurizon Therapeutics' stock price is $0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $39M | $43M | -0.8% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeurizon Therapeutics Valuation Multiples
Neurizon Therapeutics trades at 19.2x EV/Revenue multiple, and (9.4x) EV/EBITDA.
Neurizon Therapeutics Financial Valuation Multiples
As of April 18, 2026, Neurizon Therapeutics has market cap of $43M and EV of $39M.
Equity research analysts estimate Neurizon Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neurizon Therapeutics has a P/E ratio of (9.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $43M | XXX | $43M | XXX | XXX | XXX |
| EV (current) | $39M | XXX | $39M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 19.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (9.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (14.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 26.7x | XXX | XXX | XXX |
| P/E | — | XXX | (9.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (34.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Neurizon Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Neurizon Therapeutics Margins & Growth Rates
Neurizon Therapeutics' revenue in the last fiscal year grew by —.
Neurizon Therapeutics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Neurizon Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Margin | — | XXX | (206%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 152% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 37% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 203% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Neurizon Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Neurizon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Rallybio | XXX | XXX | XXX | XXX | XXX | XXX |
| Dare Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Atara Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Intervacc | XXX | XXX | XXX | XXX | XXX | XXX |
| SyntekaBio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neurizon Therapeutics M&A Activity
Neurizon Therapeutics acquired XXX companies to date.
Last acquisition by Neurizon Therapeutics was on XXXXXXXX, XXXXX. Neurizon Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Neurizon Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNeurizon Therapeutics Investment Activity
Neurizon Therapeutics invested in XXX companies to date.
Neurizon Therapeutics made its latest investment on XXXXXXXX, XXXXX. Neurizon Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Neurizon Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Neurizon Therapeutics
| When was Neurizon Therapeutics founded? | Neurizon Therapeutics was founded in 2000. |
| Where is Neurizon Therapeutics headquartered? | Neurizon Therapeutics is headquartered in Australia. |
| How many employees does Neurizon Therapeutics have? | As of today, Neurizon Therapeutics has over 14 employees. |
| Is Neurizon Therapeutics publicly listed? | Yes, Neurizon Therapeutics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Neurizon Therapeutics? | Neurizon Therapeutics trades under NUZ ticker. |
| When did Neurizon Therapeutics go public? | Neurizon Therapeutics went public in 2001. |
| Who are competitors of Neurizon Therapeutics? | Neurizon Therapeutics main competitors are Rallybio, Dare Bioscience, Atara Biotherapeutics, Intervacc. |
| What is the current market cap of Neurizon Therapeutics? | Neurizon Therapeutics' current market cap is $43M. |
| What is the current revenue of Neurizon Therapeutics? | Neurizon Therapeutics' last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of Neurizon Therapeutics? | Current revenue multiple of Neurizon Therapeutics is 19.2x. |
| Is Neurizon Therapeutics profitable? | No, Neurizon Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.